Extracellular Matrix Remodeling Biomarkers in Coronary Artery Disease
Overview
Authors
Affiliations
Atherosclerosis and one of its most serious consequences, coronary artery disease, are important sources of morbidity and mortality globally, necessitating early detection and treatment. Considering their complex pathophysiology, including several harmful processes, a comprehensive approach to diagnosis, prognosis, and therapy is very desirable. Extracellular matrix remodeling is a major component of this dangerous cascade, including the cleavage of constituents (collagen, elastin, proteoglycans) and the propagation or exacerbation of the inflammatory response. Several extracellular matrix degradation indicators have been hypothesized to correlate with the existence, severity, and prognosis of coronary artery disease. The potency of matrix metalloproteinases, notably collagenases and gelatinases, has been the most thoroughly investigated in clinical studies. Stromelysins, matrilysins, transmembrane matrix metalloproteinases, collagen and laminin turnover indicators, as well as fibronectin, have also been studied to a lesser level. Among the most well-studied markers, MMP-1, MMP-2, MMP-8, and MMP-9 have been found increased in patients with cardiovascular risk factors such as metabolic syndrome, its components (obesity, dyslipidemia, diabetes mellitus), and smoking. Increasing concentrations are detected in acute coronary syndromes compared to stable angina pectoris and healthy control groups. It should also be stressed that those extracellular matrix biomarkers may also be detected in high concentrations in other vascular pathologies such as peripheral artery disease, carotid artery disease, aortic aneurysms, and dissections. Despite the advances gained, future research should focus on their importance and, more crucially, their added utility as biomarkers in identifying persons at risk of developing overt coronary artery disease. At the same time, determining the prognosis of coronary artery disease patients using such biomarkers may be important for their adequate care.
Association between Inflammation and New-Onset Atrial Fibrillation in Acute Coronary Syndromes.
Baghina R, Crisan S, Luca S, Patru O, Lazar M, Vacarescu C J Clin Med. 2024; 13(17).
PMID: 39274304 PMC: 11396258. DOI: 10.3390/jcm13175088.
Coronary Plaque Erosion: Epidemiology, Diagnosis, and Treatment.
Theofilis P, Vlachakis P, Papanikolaou A, Karakasis P, Oikonomou E, Tsioufis K Int J Mol Sci. 2024; 25(11).
PMID: 38891972 PMC: 11171599. DOI: 10.3390/ijms25115786.
Akbari T, Kazemi Fard T, Fadaei R, Rostami R, Moradi N, Movahedi M J Cardiovasc Thorac Res. 2024; 15(4):223-230.
PMID: 38357561 PMC: 10862034. DOI: 10.34172/jcvtr.2023.31844.
Theofilis P, Oikonomou E, Tsioufis K, Tousoulis D Int J Mol Sci. 2023; 24(11).
PMID: 37298518 PMC: 10253295. DOI: 10.3390/ijms24119568.
Telomere Length: A Cardiovascular Biomarker and a Novel Therapeutic Target.
Sagris M, Theofilis P, Antonopoulos A, Tsioufis K, Tousoulis D Int J Mol Sci. 2022; 23(24).
PMID: 36555658 PMC: 9781338. DOI: 10.3390/ijms232416010.